This study, called DETERMINE, is comparing two insulin treatments, Insulin Detemir and Insulin NPH, for pregnant women with gestational diabetes or pre-existing type 2 diabetes who need insulin to manage their blood sugar. The main goal is to see if one insulin leads to fewer cases of neonatal hypoglycemia (low blood sugar in newborns) within the first 24 hours of life, and also fewer cases of prolonged neonatal hypoglycemia. You may be able to join if you are pregnant, 18 or older, and have gestational diabetes or type 2 diabetes requiring insulin. You cannot join if you have multiple pregnancies, type 1 diabetes, known allergies to these insulins, known fetal major malformations, or chronic kidney or liver problems. The current status of this study is unclear.

Study design

This study aims to enroll 336 participants to compare Insulin Detemir and Insulin NPH. It is an interventional study, meaning participants will receive one of the two insulin treatments.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The study will measure neonatal hypoglycemia within the first 24 hours of life and prolonged neonatal hypoglycemia before the baby is discharged from the hospital.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.